Kyowa Hakko Kirin Establishes Kyowa Kirin Frontier Co., Ltd.

Kyowa Hakko Kirin Co., Ltd. (Headquarters: Chiyoda-ku, Tokyo; President and CEO: Nobuo Hanai, hereinafter, “Kyowa Hakko Kirin”), established Kyowa Kirin Frontier Co., Ltd. (hereinafter, “Kyowa Kirin Frontier”) on January 18, 2017 as part of “CSV^{(Note 1)} management based on our unique business structure,” one of the core strategies set forth by Kyowa Hakko Kirin in its current Mid-term Business Plan.

Kyowa Kirin Frontier will work toward obtaining approval to manufacture and market “Authorized version ^{(Note 2)}” of NESP, a core product of Kyowa Hakko Kirin, in Japan. Through such efforts by Kyowa Kirin Frontier, it will be possible to respond to the changes in the social environment surrounding healthcare in Japan and the diversification of the needs thereof, and to meet social demands for medical cost containment.

The Kyowa Hakko Kirin Group companies strive to contribute to the health and well-being of people around the world by creating new value through the pursuit of advances in life sciences and technologies.

^{Note 1:} CSV stands for “Creating Shared Value.” It refers to realizing improved corporate value by bringing about both the “creation of social value” and the “creation of economic value” achieved through efforts to tackle pressing problems in society.

^{Note 2:} Kyowa Hakko Kirin thinks “Authorized version” is an identical drug to the branded drug in terms of active pharmaceutical ingredients, excipients and manufacturing method and which are manufactured and marketed by a company that receives the rights to exploit the branded drug’s patent from the company that owns the patent.